Calliditas therapeutics announces license agreement with viatris to register and commercialize specialty therapy for iga nephropathy in japan

Calliditas announces that it has entered into an agreement with viatris to bring nefecon®, a specialty therapy focused on downregulating iga1, to japanese patients. the agreement, worth up to $100m in upfront and milestone payments, combines calliditas' specifically formulated drug candidate with viatris' development, marketing and sales expertise.
VTRS Ratings Summary
VTRS Quant Ranking